- Home
- IVVD vs FDMT Comparison
IVVD vs FDMT Comparison
Compare IVVD & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- FDMT
- Stock Information
- Founded
- IVVD 2020
- FDMT 2013
- Country
- IVVD United States
- FDMT United States
- Employees
- IVVD N/A
- FDMT N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- FDMT Health Care
- Exchange
- IVVD Nasdaq
- FDMT Nasdaq
- Market Cap
- IVVD 412.6M
- FDMT 391.8M
- IPO Year
- IVVD 2021
- FDMT 2020
- Fundamental
- Price
- IVVD $2.57
- FDMT $10.89
- Analyst Decision
- IVVD Strong Buy
- FDMT Strong Buy
- Analyst Count
- IVVD 5
- FDMT 9
- Target Price
- IVVD $6.11
- FDMT $30.33
- AVG Volume (30 Days)
- IVVD 11.9M
- FDMT 990.0K
- Earning Date
- IVVD 11-06-2025
- FDMT 11-10-2025
- Dividend Yield
- IVVD N/A
- FDMT N/A
- EPS Growth
- IVVD N/A
- FDMT N/A
- EPS
- IVVD N/A
- FDMT N/A
- Revenue
- IVVD $50,039,000.00
- FDMT $120,000.00
- Revenue This Year
- IVVD $102.11
- FDMT $8,572.97
- Revenue Next Year
- IVVD $151.51
- FDMT $6.05
- P/E Ratio
- IVVD N/A
- FDMT N/A
- Revenue Growth
- IVVD 332.71
- FDMT 605.88
- 52 Week Low
- IVVD $0.35
- FDMT $2.24
- 52 Week High
- IVVD $3.07
- FDMT $12.34
- Technical
- Relative Strength Index (RSI)
- IVVD 64.50
- FDMT 53.40
- Support Level
- IVVD $2.38
- FDMT $10.04
- Resistance Level
- IVVD $2.70
- FDMT $11.30
- Average True Range (ATR)
- IVVD 0.25
- FDMT 0.93
- MACD
- IVVD 0.07
- FDMT -0.12
- Stochastic Oscillator
- IVVD 69.01
- FDMT 51.98
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.